TOM FRINZI
CEO, CHAIRMAN
STAAR SURGICAL CO.
WHY: In January, took over for Caren Mason, who drove sales up fourfold for its implantable collamer lens (ICL) ophthalmology devices which are used to treat a wide range of refractive eye errors.
BY THE NUMBERS: Analysts expect 2022 sales to climb 22% to $384 million this year and another 25% to $434 million in 2024.
FUTURE PLANS: Heavily dependent on sales to China, now aiming to boost U.S. sales, which represented only $10 million of its 2021 sales. The company is hoping its U.S. sales will improve as the FDA a year ago approved its EVO Visian ICL lens, its newest family of lenses that treat myopia. It aimed this year to train 600 U.S. surgeons on how to use the product.
IN THEIR WORDS: “I liked what I saw from the board’s perspective,” Frinzi told the Business Journal when he became CEO. “I’m very bullish on what Staar will become.”
